Last checked at 8 Mar 2022 07:00
IXICO plc
("IXICO" or the "Company")
Contract awarded for Phase 1b/2 Huntington's disease trial worth circa £800k
Reflection on IXICO's ability and expertise within the Huntington's disease trials space
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience announces that it has been selected by an existing US biotech client to provide PET and MRI neuroimaging services for an open-label Phase I/II dose finding study. The study will evaluate the safety, tolerability, and preliminary efficacy of the client's gene-therapy drug candidate in adult subjects with early manifest Huntington's disease (HD). The trial is due to run for just over five years and is worth circa £800k.
This is IXICO's second study for this client, having previously won a contract in 2021 to support a Multiple System Atrophy study.
Having provided centralised neuroimaging CRO services, including advanced imaging biomarker analysis, across many Huntington's disease trials, IXICO has developed and validated disease-optimised advanced analytics technology for this indication. This, together with the ability to deliver these services through the Company's proprietary TrialTracker data management platform, combined with the Company's extensive experience in supporting Huntington's disease trials, make IXICO the leading choice as the partner for this study.
Chris Hamilton, SVP Commercial at IXICO, commented: "We are delighted to play an important role in the development of this exciting gene therapy in a disease area we know extremely well and where we will deploy both our MRI and PET expertise. This new contract with an existing client reflects the confidence of our clients in the use of our services across different CNS development programmes within their portfolio. Our purpose is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders."
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| |||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Tamar Cranford-Smith (Sales) |
| |||
|
| |||
Walbrook PR Ltd | +44 (0)20 7933 8780
| |||
Paul McManus / Lianne Applegarth / | IXICO@walbrookpr.com | |||
Alice Woodings
|
| |||
About IXICO | Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews